Chagas' disease is a major concern for blood transfusion in Latin America. There are 18 endemic countries and an overall prevalence of 16-18 million people with Chagas' disease was estimated. In Brazil, the endemic area comprises more than 3.500.000km 2 involving 17 states and 2.400 cities in the Northeast, Southeast, South and Central West regions. Vector control program has been improved but the migration of infected people from endemic areas to urban centers is very high 4 . The number of transfusions in Brazil is presently reaching 5 to 6 million per year 4 . Therefore, the deferral of blood donors at risk for the infection and laboratory tests are reasonable ways to prevent transfusion transmitted Chagas' disease. Methods designed to detect Trypanosoma cruzi antigens or the whole parasite have low sensitivity because parasitemia is low or non-existent in chronically infected individuals. The most useful assay for routine screening of Chagas' disease is the detection of antibody against purified antigens or protein extracts from in vitro cultured Trypanosoma cruzi. Classical assays such as complement fixation (CFA) described by Guerreiro 
MATERIAL AND METHODS
This study was carried out at the Blood Bank of the Hospital Albert Einstein, a nonprofit private institution in the city of São Paulo. All candidates for blood donation were interviewed. The candidates were deferred as blood donors if they had any risk factors for Chagas' disease. Risk factors for Chagas' disease were considered positive when: a) the donor recognized the insect that transmits the disease (the donor was shown photographs of different species of the triatomidae), b) had lived in endemic areas in homes infested by the triatomidae, or c) had received blood transfusions.
A total of 7,999 blood donors were studied and screened by RPHA assay (Biolab, Sao Paulo, SP, Brazil) and by IFA (Biolab, São Paulo, SP, Brazil). Serum dilutions of 1/40 for RPHA and 1/20 for IFA were used for sample screening. If both reactions were negative the donor was considered negative for Chagas' disease and blood released for transfusion. If one test was positive or doubtful, it was repeated in duplicate. Samples which were repeated reactive were subjected to CFA, IFA and RPHA, performed in another laboratory with different reagents and by different personnel, as supplementary tests for diagnostic purposes.
This strategy allowed us to characterize a p a n e l o f 6 0 s a m p l e s , 4 3 o f w h i c h h a d repeatedly positive results in at least one of the screening tests. The remaining 17 samples showed negative results in all screening and supplementary tests. All samples from this panel were submitted to 3 different ELISAs (Abbott, Chicago, IL, USA; Biolab-Merieux, Rio de Janeiro, RJ, Brazil; Gull Laboratories, Salt Lake City, UT, USA).
There are no gold standards for the laboratory diagnosis of Chagas' disease. In order to estimate assay sensitivity and specificity, we defined a criteria to evaluate the ELISA tests which we called Combined Assay Performance (CAP). CAP was considered positive if confirmatory immunofluorescence was positive and at least 2 of the 3 ELISA assays were positive.
RESULTS
We screened 7,999 blood samples for Chagas' disease using RPHA and IFA. Initial reactivity (IR) on RPHA and/or IFA discarded 205 blood units (2.56%). After supplementary tests, 45 samples were positive, giving a prevalence for Chagas' disease of 0.56% (Table  1) . Based on these figures only 22% of IR samples were confirmed positive, thus illustrating the poor specificity of the screening assays. The panel for ELISA analysis (Table 2) was created among these reactive and non reactive samples. Other aspects that we have evaluated are that IFA assay is not ideal for blood donor screening because it is subjective and time consuming. Therefore, we have evaluated the performance of the ELISA assays available on the market aiming the substitution of the IFA for one of the ELISAs. Table 2 shows ELISAs compared to screening tests (IFA and RPHA) and CAP. It is clear that when 2 screening tests are positive there is complete agreement between ELISAs and CAP.
If screening is positive by immunofluorescence alone, then the confirmation rate by CAP is 10%. If both screening tests are negative, CAP is 100% negative. 
Using CAP as the gold standard the sensitivity and specificity of the screening by RPHA, IFA and the 3 different ELISAs is showed in Table 3 . 
DISCUSSION
For the blood supply safety, sensitivity is more important than specificity. In our series, IFA and ELISA had the same sensitivity when CAP was used as a gold standard. ELISA is easier to perform and quality can be better controlled in the blood banking routine. Risk factor alone is a reasonable way for preventing Chagas' disease to be transmitted by transfusion, and it is actually what has been used in the US and other areas of low prevalence of positive donors. In Brazil, this would cause the loss of many donors. Mainly because endemic areas are heterogeneous with reference to individuals at risk of active insect transmission, assuming that the whole population of a specific endemic region is potentially infected, we would be causing deferral of too many blood donors. Nevertheless, when there is a strong risk factor, for instance when the donor knows and declares that he/she was bitten by the "kissing bug", he/she is deferred and not even tested. Screening assays with high sensitivity usually generates many false positive results which is also a problem for blood banks. For instance, in the largest blood bank of Brazil, Fundação Hemocentro, São Paulo, 3.4% of all units are discarded because of one positive screening test for Chagas' disease 2 . In our institution 2.6% of all units are also discarded because of one positive screening test, and only l out of 5 of those units are considered true positive. The economic loss and problems created by anguish and fear in donors are considerable. Our results show that interview and clinical assessment are insufficient for screening Chagas infection. RPHA as a screening was not as sensitive as ELISAs and IFA. ELISA and IFA have the same sensitivity. The IFA specificity in the screening is lower then the ELISA's.
Chagas' disease is beginning to become a problem in other countries: in the United States, cases of transmission have been found 7 9 13 and in some areas, like Florida and California, there is a sizeable minority of individuals born in endemic areas, potentially capable of transmitting the disease if they donate blood. The methodology applied for screening Chagas' disease in blood donors has to have some parameters that include: simplicity, specificity, sensitivity, low cost and performance by automated laboratory equipment. Prevention of transfusion-transmitted Chagas' disease does not mean only serological testing. In highly endemic areas, some blood banks in Brazil add crystal violet to all blood units, and this method is 100% effective, very cheap, and with minimal side effects 11 . Crystal violet gives a violet hue to the blood, and not all physicians and patients find it acceptable; this is not the method we would recommend to be used in non-endemic areas as prevention of Chagas' disease in blood transfusion. The epidemiological data is also useful in low prevalence areas as a criterium to evaluate donors: however, active transmission areas of Chagas' disease are changing and the information related to old epidemiological areas are not easy to be obtained . Many individuals, now living in the US, arrived in the country decades ago, when the transmission area was much larger. São Paulo State does not have insect transmission of Chagas' disease anymore 3 . Therefore, we propose an algorithm (Figure 1 ) as a routine for prevention of Chagas' disease through blood transfusion. However, the definitive solution of Chagas' disease screening is the development of a gold standard. Polymerase chain reaction (PCR), although not suitable as a screening test at the moment is a possible candidate to be used in the future 1 
